AbbVie Inc. Proceeds from Long-Term Debt Issued
AbbVie Inc. (ABBV) reported Proceeds from Long-Term Debt Issued of $7.99 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-03
- AbbVie Inc. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- AbbVie Inc. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $7.99B, a 100.08% increase year-over-year.
- AbbVie Inc. proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- AbbVie Inc. proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00.
- AbbVie Inc. proceeds from issuance of long-term debt for fiscal 2025 was $3.99B, a 76.45% decline from fiscal 2024.
- AbbVie Inc. proceeds from issuance of long-term debt for fiscal 2024 was $16.96B.
- AbbVie Inc. proceeds from issuance of long-term debt for fiscal 2022 was $2.00B, a 100.00% increase from fiscal 2021.
- AbbVie Inc. proceeds from issuance of long-term debt for fiscal 2021 was $1.00B, a 66.67% decline from fiscal 2020.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $7.99B 10-Q · filed 2026-08-03 | $7.99B derived: sum of 3 quarters · filed 2026-08-03 | $7.99B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $7.99B 10-Q · filed 2026-05-08 | $7.99B derived: sum of 2 quarters · filed 2026-05-08 | $7.99B derived: sum of 3 quarters · filed 2026-05-08 | $7.99B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $3.99B 10-K · filed 2026-02-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-03 | $3.99B 10-Q · filed 2025-11-04 | $5.99B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $3.99B 10-Q · filed 2026-08-03 | $5.99B derived: sum of 3 quarters · filed 2026-08-03 | $5.99B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $3.99B 10-Q · filed 2026-05-08 | $5.99B derived: sum of 2 quarters · filed 2026-05-08 | $5.99B derived: sum of 3 quarters · filed 2026-05-08 | $5.99B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.00B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.00B derived: sum of 2 quarters · filed 2026-02-20 | $2.00B derived: sum of 3 quarters · filed 2026-02-20 | $16.96B 10-K · filed 2026-02-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $14.96B 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $14.96B 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $14.96B 10-Q · filed 2025-05-09 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-02-14 | $0.00 derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-05 | $0.00 derived: sum of 2 quarters · filed 2025-02-14 | $0.00 derived: sum of 3 quarters · filed 2025-02-14 | $0.00 derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $0.00 derived: sum of 2 quarters · filed 2025-02-14 | $0.00 derived: sum of 3 quarters · filed 2025-02-14 | $2.00B 10-K · filed 2025-02-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $2.00B 10-Q · filed 2023-11-06 | $2.00B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.00B 10-Q · filed 2023-08-07 | $2.00B derived: sum of 3 quarters · filed 2024-02-20 | $3.00B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $2.00B 10-Q · filed 2023-05-05 | $2.00B derived: sum of 2 quarters · filed 2024-02-20 | $3.00B derived: sum of 3 quarters · filed 2024-02-20 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.00B derived: sum of 2 quarters · filed 2024-02-20 | $1.00B 10-K · filed 2024-02-20 | |
| 2021-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.00B 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-02 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $0.00 derived: sum of 2 quarters · filed 2023-02-17 | $3.00B 10-K · filed 2023-02-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.00B 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $3.00B 10-Q · filed 2021-08-02 | |||
| 2019-12-31 | $29.95B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $31.48B 10-K · filed 2022-02-18 | ||
| 2019-09-30 | $1.53B 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $5.96B 10-K · filed 2021-02-19 | ||
| 2018-09-30 | $5.96B 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-K · filed 2018-02-16 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-07 | |||
| 2016-12-31 | $3.86B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.86B derived: sum of 2 quarters · filed 2019-02-27 | $11.63B 10-K · filed 2019-02-27 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $7.77B 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $7.77B 10-Q · filed 2017-08-07 | |||
| 2015-12-31 | $4.00B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $4.00B derived: sum of 2 quarters · filed 2018-02-16 | $20.66B 10-K · filed 2018-02-16 | |
| 2015-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $16.66B 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | $16.66B 10-Q · filed 2016-08-05 | |||
| 2012-12-31 | $14.59B 10-K · filed 2015-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |